BON
NASDAQ · Consumer Defensive · Packaged Foods · KY
Next report
Analyst consensus
- Next report date
- Dec 2, 2026
- EPS estimate
- —
- Revenue estimate
- —
Latest reported
- Last report date
- Jan 23, 2026
- EPS actual
- -$0.79
- EPS estimate
- —
- Revenue actual
- $10.7M
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 1
- EPS misses (12Q)
- 3
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -26.8%
- Revenue beats (12Q)
- 0
Q4 FY2022 · Feb 10, 2023
AI summary of management’s prepared remarks and analyst Q&A · For informational purposes only, not investment advice
Management highlights
Manufacturing Facilities
- Two facilities in Xi'an; Yumen Plant first phase construction completed as scheduled, expected to finish in May 2023, increasing fragrance compounds and bio-active food ingredients production capacity. Second phase for new proprietary products.
Proprietary Products
- FeatherPure female personal care product expected to bring ~$3 million in revenue over two years. Broccoli-based probiotic powdery drink launched, with plans for other cruciferous vegetable-based products like immune boosters, digestive health products, etc.
Growth Strategies
- Plan to expand product line with 2-3 new raw material categories. Carry out 2-3 mergers/acquisitions to enhance bio manufacturing technology and sales networking. Expand globally in US, Japan, Europe, SE Asia.
Guidance
Yumen Plant
- First phase expected to complete in May 2023, increasing production capacity and potentially driving 130% annualized revenue growth. ### Overseas Sales
- Expect overseas sales to pick up in fiscal year 2023 as global logistics improve post-China reopening.
Segment performance
In fiscal year 2022, Bon Natural Life generated approximately $29.9 million in revenue, a 17.3% increase from the prior year. Fragrance compounds: Revenue increased 7.6% from $12.7 million to $13.7 million. Health supplements (powder drink): Increased 7.4% from $6.7 million to $7.1 million. Bioactive food ingredients: Grew 38.5% from $6.1 million to $9.1 million. Domestic China revenue was $28.8 million (96.1% of total), while overseas sales were $1.2 million (3.9% of total).
Risks & headwinds
- Supply chain issues impacted fragrance compounds due to raw material shortages and COVID-19-related logistics disruptions. - Initial delay in Yumen Plant completion, but management expects no further delays post-China reopening.
Analyst Q&A
Q: Regarding the delay in the Yumen plant completion, do you expect it to finish in May 2023 and what about production capacity and demand?
A: Management does not foresee further delays, expects completion in May 2023. Phase one increases fragrance compounds and bio-active food ingredients production capacity, with existing demand and plans to meet increased production.
Q: Why did overseas sales decline in 2022 and will the plan be adjusted?
A: Overseas sales declined due to port congestion in 2022 and global supply chain disruptions. Company expects overseas sales to pick up in fiscal year 2023.
Q: About accounts receivable over $6 million, any bad debt provisions?
A: Payment terms are 90 days, all payments on schedule, no bad debt provision as all payments were made according to schedule by January 2023
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Dec 2, 2026